Chapter 39
Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies
Whitney S. Gibbs,
Natalie E. Scholpa,
Craig C. Beeson,
Rick G. Schnellmann,
Whitney S. Gibbs
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Search for more papers by this authorNatalie E. Scholpa
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Search for more papers by this authorCraig C. Beeson
Department of Drug Discovery and Biomedical Sciences, College of Graduate Studies, Medical University of South Carolina, Charleston, SC, USA
Search for more papers by this authorRick G. Schnellmann
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Southern Arizona VA Health Care System, Tucson, AZ, USA
Search for more papers by this authorWhitney S. Gibbs,
Natalie E. Scholpa,
Craig C. Beeson,
Rick G. Schnellmann,
Whitney S. Gibbs
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Search for more papers by this authorNatalie E. Scholpa
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Search for more papers by this authorCraig C. Beeson
Department of Drug Discovery and Biomedical Sciences, College of Graduate Studies, Medical University of South Carolina, Charleston, SC, USA
Search for more papers by this authorRick G. Schnellmann
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA
Southern Arizona VA Health Care System, Tucson, AZ, USA
Search for more papers by this authorBook Editor(s):Yvonne Will PhD, ATS Fellow,
James A. Dykens,
Yvonne Will PhD, ATS Fellow
Pfizer Drug Safety R&D, Groton, CT, USA
Search for more papers by this authorSummary
Mitochondrial dysfunction is a key pathophysiological mediator in a variety of disease states, including cardiovascular disease, metabolic syndrome, neurodegeneration, and acute organ injury. Pharmacological activation of mitochondrial biogenesis enhances mitochondrial content and oxidative metabolism and improves organ function in conditions involving mitochondrial dysfunction. Due to the complexity of signaling cascades and transcriptional complexes that promote the assembly and function of mitochondria, identification of specific activators of mitochondrial biogenesis is limited. This chapter provides rationale for mitochondrial biogenesis as a therapeutic strategy, discusses the role of mitochondrial dysfunction in acute and chronic disease, and outlines the current state of pharmacological activators of mitochondrial biogenesis and their effects on disease outcomes.
References
- Adibhatla, R. M. and J. F. Hatcher (2010). “Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities.” Antioxid Redox Signal 12(1): 125–169.
- Alexander, S. P., A. P. Davenport, E. Kelly, N. Marrion, J. A. Peters, H. E. Benson, E. Faccenda, A. J. Pawson, J. L. Sharman, C. Southan and J. A. Davies (2015). “The concise guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.” Br J Pharmacol 172(24): 5744–5869.
- Andreadou, I., E. K. Iliodromitis, D. Farmakis and D. T. Kremastinos (2009). “To prevent, protect and save the ischemic heart: antioxidants revisited.” Expert Opin Ther Targets 13(8): 945–956.
- Ansquer, J. C., C. Foucher, P. Aubonnet and K. Le Malicot (2009). “Fibrates and microvascular complications in diabetes--insight from the FIELD study.” Curr Pharm Des 15(5): 537–552.
- Antonini, A., K. L. Leenders, R. Spiegel, D. Meier, P. Vontobel, M. Weigell-Weber, R. Sanchez-Pernaute, J. G. de Yébenez, P. Boesiger, A. Weindl and R. P. Maguire (1996). “Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.” Brain 119(6): 2085–2095.
- Anwar, M. A., T. S. Al Shehabi and A. H. Eid (2016). “Inflammogenesis of secondary spinal cord injury.” Front Cell Neurosci 10: 98.
-
Ashabi, G., M. Ramin, P. Azizi, Z. Taslimi, S. Z. Alamdary, A. Haghparast, N. Ansari, F. Motamedi and F. Khodagholi (2012). “ERK and p38 inhibitors attenuate memory deficits and increase CREB phosphorylation and PGC-1alpha levels in Abeta-injected rats.” Behav Brain Res
232(1): 165–173.
10.1016/j.bbr.2012.04.006 Google Scholar
- Banoei, M. M., M. Houshmand, M. S. S. Panahi, P. Shariati, M. Rostami, M. D. Manshadi and T. Majidizadeh (2007). “Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant Huntingtin protein and CAG repeats expansion?!” Cell Mol Neurobiol 27(7): 867–875.
- Baptiste, D. C. and M. G. Fehlings (2006). “Pharmacological approaches to repair the injured spinal cord.” J Neurotrauma 23(3–4): 318–334.
- Barroso, E., R. Rodriguez-Calvo, L. Serrano-Marco, A. M. Astudillo, J. Balsinde, X. Palomer and M. Vazquez-Carrera (2011). “The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.” Endocrinology 152(5): 1848–1859.
- Beattie, M. S., G. E. Hermann, R. C. Rogers and J. C. Bresnahan (2002). “Cell death in models of spinal cord injury.” Prog Brain Res 137: 37–47.
- Bellomo, R., J. A. Kellum and C. Ronco (2012). “Acute kidney injury.” Lancet 380(9843): 756–766.
- Bender, A., K. J. Krishnan, C. M. Morris, G. A. Taylor, A. K. Reeve, R. H. Perry, E. Jaros, J. S. Hersheson, J. Betts, T. Klopstock, R. W. Taylor and D. M. Turnbull (2006). “High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease.” Nat Genet 38(5): 515–517.
- Bergeron, R., J. M. Ren, K. S. Cadman, I. K. Moore, P. Perret, M. Pypaert, L. H. Young, C. F. Semenkovich and G. I. Shulman (2001). “Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis.” Am J Physiol Endocrinol Metab 281(6): E1340–E1346.
- Bernardo, A., D. Bianchi, V. Magnaghi and L. Minghetti (2009). “Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.” J Neuropathol Exp Neurol 68(7): 797–808.
- Bhatt, J. K., S. Thomas and M. J. Nanjan (2012). “Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus.” Nutr Res 32(7): 537–541.
-
Bikman, B. T., D. Zheng, M. A. Reed, R. C. Hickner, J. A. Houmard and G. L. Dohm (2010). “Lipid-induced insulin resistance is prevented in lean and obese myotubes by AICAR treatment.” Am J Physiol Regul Integr Comp Physiol
298(6): R1692–R1699.
10.1152/ajpregu.00190.2009 Google Scholar
- Blanchet, J., F. Longpre, G. Bureau, M. Morissette, T. DiPaolo, G. Bronchti and M. G. Martinoli (2008). “Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.” Prog Neuropsychopharmacol Biol Psychiatry 32(5): 1243–1250.
- Bluher, M., S. Engeli, N. Kloting, J. Berndt, M. Fasshauer, S. Batkai, P. Pacher, M. R. Schon, J. Jordan and M. Stumvoll (2006). “Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.” Diabetes 55(11): 3053–3060.
- Bogacka, I., H. Xie, G. A. Bray and S. R. Smith (2005). “Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.” Diabetes 54(5): 1392–1399.
- Bolten, C. W., P. M. Blanner, W. G. McDonald, N. R. Staten, R. A. Mazzarella, G. B. Arhancet, M. F. Meier, D. J. Weiss, P. M. Sullivan, A. E. Hromockyj, R. F. Kletzien and J. R. Colca (2007). “Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.” Gene Regul Syst Bio 1: 73–82.
-
Boon, H., M. Bosselaar, S. F. Praet, E. E. Blaak, W. H. Saris, A. J. Wagenmakers, S. L. McGee, C. J. Tack, P. Smits, M. Hargreaves and L. J. van Loon (2008). “Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients.” Diabetologia
51(10): 1893–1900.
10.1007/s00125-008-1108-7 Google Scholar
- Bowling, A. C., J. B. Schulz, R. H. Brown Jr. and M. F. Beal (1993). “Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis.” J Neurochem 61(6): 2322–2325.
- Brasnyo, P., G. A. Molnar, M. Mohas, L. Marko, B. Laczy, J. Cseh, E. Mikolas, I. A. Szijarto, A. Merei, R. Halmai, L. G. Meszaros, B. Sumegi and I. Wittmann (2011). “Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.” Br J Nutr 106(3): 383–389.
- Brunet, A., L. B. Sweeney, J. F. Sturgill, K. F. Chua, P. L. Greer, Y. Lin, H. Tran, S. E. Ross, R. Mostoslavsky, H. Y. Cohen, L. S. Hu, H. L. Cheng, M. P. Jedrychowski, S. P. Gygi, D. A. Sinclair, F. W. Alt and M. E. Greenberg (2004). “Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.” Science 303(5666): 2011–2015.
- Calleri, E., G. Pochetti, K. S. Dossou, A. Laghezza, R. Montanari, D. Capelli, E. Prada, F. Loiodice, G. Massolini, M. Bernier and R. Moaddel (2014). “Resveratrol and its metabolites bind to PPARs.” Chembiochem 15(8): 1154–1160.
- Cameron, R. B., C. C. Beeson and R. G. Schnellmann (2017). “Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol.” Sci Rep 7(1): 10578.
- Canto, C. and J. Auwerx (2009). “PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure.” Curr Opin Lipidol 20(2): 98–105.
- Canto, C., Z. Gerhart-Hines, J. N. Feige, M. Lagouge, L. Noriega, J. C. Milne, P. J. Elliott, P. Puigserver and J. Auwerx (2009). “AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity.” Nature 458(7241): 1056–1060.
- Capllonch-Amer, G., M. Sbert-Roig, B. M. Galmes-Pascual, A. M. Proenza, I. Llado, M. Gianotti and F. J. Garcia-Palmer (2014). “Estradiol stimulates mitochondrial biogenesis and adiponectin expression in skeletal muscle.” J Endocrinol 221(3): 391–403.
- Caramelo, C., M. V. Alvarez-Arroyo, S. Yague, Y. Suzuki, M. A. Castilla, L. Velasco, F. R. Gonzalez-Pacheco and A. Tejedor (2004). “Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward.” Nephrol Dial Transplant 19(2): 285–288.
- Chattipakorn, S. C., S. Thummasorn, J. Sanit and N. Chattipakorn (2014). “Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart.” J Geriatr Cardiol 11(2): 151–157.
- Chaturvedi, R. K., P. Adhihetty, S. Shukla, T. Hennessy, N. Calingasan, L. Yang, A. Starkov, M. Kiaei, M. Cannella, J. Sassone, A. Ciammola, F. Squitieri and M. F. Beal (2009). “Impaired PGC-1α function in muscle in Huntington's disease.” Hum Mol Genet 18(16): 3048–3065.
- Chaturvedi, R. K. and M. F. Beal (2013). “Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases.” Mol Cell Neurosci 55: 101–114.
- Chen, J. Q., T. R. Brown and J. D. Yager (2008). “Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria.” Adv Exp Med Biol 630: 1–18.
- Chen, S. D., T. K. Lin, D. I. Yang, S. Y. Lee, F. Z. Shaw, C. W. Liou and Y. C. Chuang (2010). “Protective effects of peroxisome proliferator-activated receptors γ coactivator-1α against neuronal cell death in the hippocampal CA1 subfield after transient global ischemia.” J Neurosci Res 88(3): 605–613.
- Chen, S. D., D. I. Yang, T. K. Lin, F. Z. Shaw, C. W. Liou and Y. C. Chuang (2011). “Roles of oxidative stress, apoptosis, PGC-1alpha and mitochondrial biogenesis in cerebral ischemia.” Int J Mol Sci 12(10): 7199–7215.
-
Cheng, H., Y. Shang, L. Jiang, T.-l. Shi and L. Wang (2016). “The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.” Int J Neurosci
126(4): 299–307.
10.3109/00207454.2015.1015722 Google Scholar
- Choi, D. W. and S. M. Rothman (1990). “The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death.” Annu Rev Neurosci 13: 171–182.
- Choi, J. M., H. K. Shin, K. Y. Kim, J. H. Lee and K. W. Hong (2002). “Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats.” J Pharmacol Exp Ther 300(3): 787–793.
- Collier, J. B., R. M. Whitaker, S. T. Eblen and R. G. Schnellmann (2016). “Rapid renal regulation of peroxisome proliferator-activated receptor gamma coactivator-1alpha by extracellular signal-regulated kinase 1/2 in physiological and pathological conditions.” J Biol Chem 291(52): 26850–26859.
- Coskun, P., J. Wyrembak, S. E. Schriner, H. W. Chen, C. Marciniack, F. Laferla and D. C. Wallace (2012). “A mitochondrial etiology of Alzheimer and Parkinson disease.” Biochim Biophys Acta 1820(5): 553–564.
- Cozzolino, M. and M. T. Carrì (2012). “Mitochondrial dysfunction in ALS.” Prog Neurobiol 97(2): 54–66.
- Crugnola, V., C. Lamperti, V. Lucchini, D. Ronchi, L. Peverelli, A. Prelle, M. Sciacco, A. Bordoni, E. Fassone, F. Fortunato, S. Corti, V. Silani, N. Bresolin, S. Di Mauro, G. P. Comi and M. Moggio (2010). “Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis.” Arch Neurol 67(7): 849–854.
-
Csiszar, A., N. Labinskyy, J. T. Pinto, P. Ballabh, H. Zhang, G. Losonczy, K. Pearson, R. de Cabo, P. Pacher, C. Zhang and Z. Ungvari (2009). “Resveratrol induces mitochondrial biogenesis in endothelial cells.” Am J Physiol Heart Circ Physiol
297(1): H13–H20.
10.1152/ajpheart.00368.2009 Google Scholar
- Cui, L., H. Jeong, F. Borovecki, C. N. Parkhurst, N. Tanese and D. Krainc (2006). “Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.” Cell 127(1): 59–69.
- Dabrowska, A., J. L. Venero, R. Iwasawa, M.-k. Hankir, S. Rahman, A. Boobis and N. Hajji (2015). “PGC-1α controls mitochondrial biogenesis and dynamics in lead-induced neurotoxicity.” Aging (Albany NY) 7(9): 629–643.
- Dasgupta, B. and J. Milbrandt (2007). “Resveratrol stimulates AMP kinase activity in neurons.” Proc Natl Acad Sci U S A 104(17): 7217–7222.
- De Rasmo, D., A. Signorile, E. Roca and S. Papa (2009). “cAMP response element-binding protein (CREB) is imported into mitochondria and promotes protein synthesis.” FEBS J 276(16): 4325–4333.
-
De Toni, L., G. Strapazzon, L. Gianesello, N. Caretta, C. Pilon, A. Bruttocao and C. Foresta (2011). “Effects of type 5-phosphodiesterase inhibition on energy metabolism and mitochondrial biogenesis in human adipose tissue ex vivo.” J Endocrinol Invest
34(10): 738–741.
10.1007/BF03346724 Google Scholar
- DeMarch, Z., C. Giampa, S. Patassini, A. Martorana, G. Bernardi and F. R. Fusco (2007). “Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity.” Neurobiol Dis 25(2): 266–273.
- Doherty, R. E. (2000). “A history of the production and use of carbon tetrachloride, tetrachloroethylene, trichloroethylene and 1,1,1-trichloroethane in the United States: part 1. Historical background; carbon tetrachloride and tetrachloroethylene.” J Environ Forensic 1(2): 69–81.
- Dudzinski, D. M. and T. Michel (2007). “Life history of eNOS: partners and pathways.” Cardiovasc Res 75(2): 247–260.
- Dumont, M., C. Stack, C. Elipenahli, S. Jainuddin, M. Gerges, N. Starkova, N. Y. Calingasan, L. Yang, D. Tampellini, A. A. Starkov, R. B. Chan, G. Di Paolo, A. Pujol and M. F. Beal (2012). “Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.” Hum Mol Genet 21(23): 5091–5105.
- Feige, J. N., M. Lagouge, C. Canto, A. Strehle, S. M. Houten, J. C. Milne, P. D. Lambert, C. Mataki, P. J. Elliott and J. Auwerx (2008). “Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation.” Cell Metab 8(5): 347–358.
- Feigin, A., K. L. Leenders, J. R. Moeller, J. Missimer, G. Kuenig, P. Spetsieris, A. Antonini and D. Eidelberg (2001). “Metabolic network abnormalities in early Huntington's disease: an [18F]FDG PET study.” J Nucl Med 42(11): 1591–1595.
- Feldkamp, T., A. Kribben and J. M. Weinberg (2005). “Assessment of mitochondrial membrane potential in proximal tubules after hypoxia-reoxygenation.” Am J Physiol Renal Physiol 288(6): F1092–F1102.
- Fernandez-Marcos, P. J. and J. Auwerx (2011). “Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis.” Am J Clin Nutr 93(4): 884s–890s.
- Flower, D. R. (1999). “Modelling G-protein-coupled receptors for drug design.” Biochim Biophys Acta 1422(3): 207–234.
- Friedman, J. R. and J. Nunnari (2014). “Mitochondrial form and function.” Nature 505(7483): 335–343.
-
Fujita, K., M. Yamauchi, K. Shibayama, M. Ando, M. Honda and Y. Nagata (1996). “Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis.” J Neurosci Res
45(3): 276–281.
10.1002/(SICI)1097-4547(19960801)45:3<276::AID-JNR9>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- Funk, J. A. and R. G. Schnellmann (2012). “Persistent disruption of mitochondrial homeostasis after acute kidney injury.” Am J Physiol Renal Physiol 302(7): F853–F864.
- Funk, J. A. and R. G. Schnellmann (2013). “Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1alpha activation following ischemia-reperfusion injury.” Toxicol Appl Pharmacol 273(2): 345–354.
- Gan, X., S. Huang, L. Wu, Y. Wang, G. Hu, G. Li, H. Zhang, H. Yu, R. H. Swerdlow, J. X. Chen and S. S. Yan (2014). “Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell.” Biochim Biophys Acta 1842(2): 220–231.
-
Garcha, R. S. and A. D. Hughes (2006). “CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels.” J Renin Angiotensin Aldosterone Syst
7(2): 87–91.
10.3317/jraas.2006.014 Google Scholar
- Garg, U. C. and A. Hassid (1989). “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.” J Clin Invest 83(5): 1774–1777.
-
Garrett, S. M., R. M. Whitaker, C. C. Beeson and R. G. Schnellmann (2014). “Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury.” J Pharmacol Exp Ther
350(2): 257–264.
10.1124/jpet.114.214700 Google Scholar
-
Gibbs, W. S., R. A. Weber, R. G. Schnellmann and D. L. Adkins (2016). “Disrupted mitochondrial genes and inflammation following stroke.” Life Sci
166: 139–148.
10.1016/j.lfs.2016.09.021 Google Scholar
- Gibbs, W. S., S. M. Garrett, C. C. Beeson and R. G. Schnellmann (2017). “ Identification of Dual Mechanisms Mediating 5-hydroxytryptamine Receptor 1F Induced Mitochondrial Biogenesis.” Am J Physiol Renal Physiol: ajprenal.00324.02017.
- Gong, B., O. V. Vitolo, F. Trinchese, S. Liu, M. Shelanski and O. Arancio (2004). “Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.” J Clin Invest 114(11): 1624–1634.
- Grabacka, M., M. Pierzchalska and K. Reiss (2013). “Peroxisome proliferator activated receptor alpha ligands as anticancer drugs targeting mitochondrial metabolism.” Curr Pharm Biotechnol 14(3): 342–356.
- Graumann, U., M. F. Ritz and O. Hausmann (2011). “Necessity for re-vascularization after spinal cord injury and the search for potential therapeutic options.” Curr Neurovasc Res 8(4): 334–341.
- Guo, P., H. Pi, S. Xu, L. Zhang, Y. Li, M. Li, Z. Cao, L. Tian, J. Xie, R. Li, M. He, Y. Lu, C. Liu, W. Duan, Z. Yu and Z. Zhou (2014). “Melatonin improves mitochondrial function by promoting MT1/SIRT1/PGC-1 alpha-dependent mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro.” Toxicol Sci 142(1): 182–195.
- Gutsaeva, D. R., M. S. Carraway, H. B. Suliman, I. T. Demchenko, H. Shitara, H. Yonekawa and C. A. Piantadosi (2008). “Transient hypoxia stimulates mitochondrial biogenesis in brain subcortex by a neuronal nitric oxide synthase-dependent mechanism.” J Neurosci 28(9): 2015–2024.
- Handschin, C., J. Rhee, J. Lin, P. T. Tarr and B. M. Spiegelman (2003). “An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle.” Proc Natl Acad Sci U S A 100(12): 7111–7116.
- Handschin, C. and B. M. Spiegelman (2006). “Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism.” Endocr Rev 27(7): 728–735.
-
Harmon, J. L., L. P. Wills, C. E. McOmish, E. Y. Demireva, J. A. Gingrich, C. C. Beeson and R. G. Schnellmann (2016). “5-HT2 receptor regulation of mitochondrial genes: unexpected pharmacological effects of agonists and antagonists.” J Pharmacol Exp Ther
357(1): 1–9.
10.1124/jpet.115.228395 Google Scholar
- Hart, M. N., P. A. Cancilla, S. Frommes and A. Hirano (1977). “Anterior horn cell degeneration and Bunina-type inclusions associated with dementia.” Acta Neuropathol 38(3): 225–228.
- Hausenloy, D. J. and D. M. Yellon (2013). “Myocardial ischemia-reperfusion injury: a neglected therapeutic target.” J Clin Invest 123(1): 92–100.
- Heneka, M. T., A. Fink and G. Doblhammer (2015). “Effect of pioglitazone medication on the incidence of dementia.” Ann Neurol 78(2): 284–294.
- Hirai, K., G. Aliev, A. Nunomura, H. Fujioka, R. L. Russell, C. S. Atwood, A. B. Johnson, Y. Kress, H. V. Vinters, M. Tabaton, S. Shimohama, A. D. Cash, S. L. Siedlak, P. L. Harris, P. K. Jones, R. B. Petersen, G. Perry and M. A. Smith (2001). “Mitochondrial abnormalities in Alzheimer's disease.” J Neurosci 21(9): 3017–3023.
- Hirsch, T., S. A. Susin, I. Marzo, P. Marchetti, N. Zamzami and G. Kroemer (1998). “Mitochondrial permeability transition in apoptosis and necrosis.” Cell Biol Toxicol 14(2): 141–145.
- Ho, D. J., N. Y. Calingasan, E. Wille, M. Dumont and M. F. Beal (2010). “Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease.” Exp Neurol 225(1): 74–84.
- Hoshino, D., Y. Yoshida, G. P. Holloway, J. Lally, H. Hatta and A. Bonen (2012). “Clenbuterol, a beta2-adrenergic agonist, reciprocally alters PGC-1 alpha and RIP140 and reduces fatty acid and pyruvate oxidation in rat skeletal muscle.” Am J Physiol Regul Integr Comp Physiol 302(3): R373–R384.
-
Hu, J., Y. Lang, Y. Cao, T. Zhang and H. Lu (2015). “The neuroprotective effect of tetramethylpyrazine against contusive spinal cord injury by activating PGC-1α in rats.” Neurochem Res
40(7): 1393–1401.
10.1007/s11064-015-1606-1 Google Scholar
- Hu, J., Y. Lang, T. Zhang, S. Ni and H. Lu (2016). “Lentivirus-mediated PGC-1α overexpression protects against traumatic spinal cord injury in rats.” Neuroscience 328: 40–49.
-
Ibarra, A., D. Correa, K. Willms, M. T. Merchant, G. Guizar-Sahagun, I. Grijalva and I. Madrazo (2003). “Effects of cyclosporin-A on immune response, tissue protection and motor function of rats subjected to spinal cord injury.” Brain Res
979(1–2): 165–178.
10.1016/S0006-8993(03)02898-1 Google Scholar
-
Ibarra, A., G. Guizar-Sahagun, D. Correa, R. Kretschmer, I. Grijalva, F. J. Flores-Murrieta, G. Castaneda-Hernandez, A. Odor, R. M. Lopez, R. Franco-Bourland, A. L. Espitia, H. Salgado-Ceballos and I. Madrazo (1996a). “Alteration of cyclosporin-A pharmacokinetics after experimental spinal cord injury.” J Neurotrauma
13(5): 267–272.
10.1089/neu.1996.13.267 Google Scholar
- Ibarra, A., J. Reyes, S. Martinez, D. Correa, G. Guizar-Sahagun, I. Grijalva, G. Castaneda-Hernandez, F. J. Flores-Murrieta, R. Franco-Bourland and I. Madrazo (1996b). “Use of cyclosporin-A in experimental spinal cord injury: design of a dosing strategy to maintain therapeutic levels.” J Neurotrauma 13(10): 569–572.
- Ikeuchi, M., H. Matsusaka, D. Kang, S. Matsushima, T. Ide, T. Kubota, T. Fujiwara, N. Hamasaki, A. Takeshita, K. Sunagawa and H. Tsutsui (2005). “Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction.” Circulation 112(5): 683–690.
- Irwin, R. W., J. Yao, R. T. Hamilton, E. Cadenas, R. D. Brinton and J. Nilsen (2008). “Progesterone and estrogen regulate oxidative metabolism in brain mitochondria.” Endocrinology 149(6): 3167–3175.
-
Ito, H., A. Nakano, M. Kinoshita and A. Matsumori (2003). “Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model.” Lab Invest
83(12): 1715–1721.
10.1097/01.LAB.0000106724.29121.DA Google Scholar
- Jager, S., C. Handschin, J. St-Pierre and B. M. Spiegelman (2007). “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha.” Proc Natl Acad Sci U S A 104(29): 12017–12022.
- Jassem, W., S. V. Fuggle, M. Rela, D. D. Koo and N. D. Heaton (2002). “The role of mitochondria in ischemia/reperfusion injury.” Transplantation 73(4): 493–499.
- Jassem, W. and N. D. Heaton (2004). “The role of mitochondria in ischemia/reperfusion injury in organ transplantation.” Kidney Int 66(2): 514–517.
- Jesinkey, S. R., J. A. Funk, L. J. Stallons, L. P. Wills, J. K. Megyesi, C. C. Beeson and R. G. Schnellmann (2014a). “Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury.” J Am Soc Nephrol 25(6): 1157–1162.
-
Jesinkey, S. R., M. C. Korrapati, K. A. Rasbach, C. C. Beeson and R. G. Schnellmann (2014b). “Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.” J Pharmacol Exp Ther
351(3): 663–673.
10.1124/jpet.114.217380 Google Scholar
- Jiang, H. K., Y. Miao, Y. H. Wang, M. Zhao, Z. H. Feng, X. J. Yu, J. K. Liu and W. J. Zang (2014). “Aerobic interval training protects against myocardial infarction-induced oxidative injury by enhancing antioxidase system and mitochondrial biosynthesis.” Clin Exp Pharmacol Physiol 41(3): 192–201.
- Jurado, F., J. M. Bellon, J. A. Pareja, A. Golitsin, L. Millan, G. Pascual and J. Bujan (1998). “Effects of ischaemia-reperfusion and cyclosporin-A on cardiac muscle ultrastructure.” Histol Histopathol 13(3): 761–774.
- Kalogeris, T., Y. Bao and R. J. Korthuis (2014). “Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning.” Redox Biol 2: 702–714.
- Kang, J.-W., J.-M. Hong and S.-M. Lee (2016). “Melatonin enhances mitophagy and mitochondrial biogenesis in rats with carbon tetrachloride-induced liver fibrosis.” J Pineal Res 60(4): 383–393.
-
Karaki, H., K. Sato, H. Ozaki and K. Murakami (1988). “Effects of sodium nitroprusside on cytosolic calcium level in vascular smooth muscle.” Eur J Pharmacol
156(2): 259–266.
10.1016/0014-2999(88)90329-9 Google Scholar
- Khan, S. M., D. S. Cassarino, N. N. Abramova, P. M. Keeney, M. K. Borland, P. A. Trimmer, C. T. Krebs, J. C. Bennett, J. K. Parks, R. H. Swerdlow, W. D. Parker Jr. and J. P. Bennett Jr. (2000). “Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways.” Ann Neurol 48(2): 148–155.
- Kim, D., M. D. Nguyen, M. M. Dobbin, A. Fischer, F. Sananbenesi, J. T. Rodgers, I. Delalle, J. A. Baur, G. Sui, S. M. Armour, P. Puigserver, D. A. Sinclair and L. H. Tsai (2007). “SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis.” EMBO J 26(13): 3169–3179.
- Kim, J., J. P. Moody, C. K. Edgerly, O. L. Bordiuk, K. Cormier, K. Smith, M. Flint Beal and R. J. Ferrante (2010). “Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease.” Hum Mol Genet 19(20): 3919–3935.
- Kleiner, S., V. Nguyen-Tran, O. Bare, X. Huang, B. Spiegelman and Z. Wu (2009). “PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function.” J Biol Chem 284(28): 18624–18633.
- Klinge, C. M. (2008). “Estrogenic control of mitochondrial function and biogenesis.” J Cell Biochem 105(6): 1342–1351.
- Lagouge, M., C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver and J. Auwerx (2006). “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha.” Cell 127(6): 1109–1122.
- Le Gouill, E., M. Jimenez, C. Binnert, P. Y. Jayet, S. Thalmann, P. Nicod, U. Scherrer and P. Vollenweider (2007). “Endothelial nitric oxide synthase (eNOS) knockout mice have defective mitochondrial beta-oxidation.” Diabetes 56(11): 2690–2696.
- Lee, J., C. H. Kim, D. K. Simon, L. R. Aminova, A. Y. Andreyev, Y. E. Kushnareva, A. N. Murphy, B. E. Lonze, K. S. Kim, D. D. Ginty, R. J. Ferrante, H. Ryu and R. R. Ratan (2005). “Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival.” J Biol Chem 280(49): 40398–40401.
- Lempiainen, J., P. Finckenberg, J. Levijoki and E. Mervaala (2012). “AMPK activator AICAR ameliorates ischaemia reperfusion injury in the rat kidney.” Br J Pharmacol 166(6): 1905–1915.
- Leonard, B. E. (1996). “Serotonin receptors and their function in sleep, anxiety disorders and depression.” Psychother Psychosom 65(2): 66–75.
- Lerin, C., J. T. Rodgers, D. E. Kalume, S. H. Kim, A. Pandey and P. Puigserver (2006). “GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha.” Cell Metab 3(6): 429–438.
- Li, X., B. Monks, Q. Ge and M. J. Birnbaum (2007). “Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator.” Nature 447(7147): 1012–1016.
- Li, X., H. Wang, Y. Gao, L. Li, C. Tang, G. Wen, Y. Yang, Z. Zhuang, M. Zhou, L. Mao and Y. Fan (2016). “Quercetin induces mitochondrial biogenesis in experimental traumatic brain injury via the PGC-1alpha signaling pathway.” Am J Transl Res 8(8): 3558–3566.
- Libri, V., A. P. Brown, G. Gambarota, J. Haddad, G. S. Shields, H. Dawes, D. J. Pinato, E. Hoffman, P. J. Elliot, G. P. Vlasuk, E. Jacobson, M. R. Wilkins and P. M. Matthews (2012). “A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.” PLoS One 7(12): e51395.
- Lim, S. Y., S. M. Davidson, D. J. Hausenloy and D. M. Yellon (2007). “Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore.” Cardiovasc Res 75(3): 530–535.
-
Long, J., H. Gao, L. Sun, J. Liu and X. Zhao-Wilson (2009). “Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model.” Rejuvenation Res
12(5): 321–331.
10.1089/rej.2009.0877 Google Scholar
- Mattingly, K. A., M. M. Ivanova, K. A. Riggs, N. S. Wickramasinghe, M. J. Barch and C. M. Klinge (2008). “Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis.” Mol Endocrinol 22(3): 609–622.
- McEwen, M. L., P. G. Sullivan, A. G. Rabchevsky and J. E. Springer (2011). “Targeting mitochondrial function for the treatment of acute spinal cord injury.” Neurotherapeutics 8(2): 168–179.
- McGill, J. K. and M. F. Beal (2006). “PGC-1α, a new therapeutic target in Huntington's disease?” Cell 127(3): 465–468.
- McGill, M. R., M. R. Sharpe, C. D. Williams, M. Taha, S. C. Curry and H. Jaeschke (2012). “The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation.” J Clin Invest 122(4): 1574–1583.
- McMahon, S. S., S. Albermann, G. E. Rooney, C. Moran, J. Hynes, Y. Garcia, P. Dockery, T. O'Brien, A. J. Windebank and F. P. Barry (2009). “Effect of cyclosporin A on functional recovery in the spinal cord following contusion injury.” J Anat 215(3): 267–279.
- Mensink, M., M. K. Hesselink, A. P. Russell, G. Schaart, J. P. Sels and P. Schrauwen (2007). “Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.” Int J Obes (Lond) 31(8): 1302–1310.
- Menzies, K. J., K. Singh, A. Saleem and D. A. Hood (2013). “Sirtuin 1-mediated effects of exercise and resveratrol on mitochondrial biogenesis.” J Biol Chem 288(10): 6968–6979.
- Milne, J. C., P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith, D. J. Gagne, L. Jin, O. Boss, R. B. Perni, C. B. Vu, J. E. Bemis, R. Xie, J. S. Disch, P. Y. Ng, J. J. Nunes, A. V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D. A. Sinclair, J. M. Olefsky, M. R. Jirousek, P. J. Elliott and C. H. Westphal (2007). “Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.” Nature 450(7170): 712–716.
- Mitchell, S. J., A. Martin-Montalvo, E. M. Mercken, H. H. Palacios, T. M. Ward, G. Abulwerdi, R. K. Minor, G. P. Vlasuk, J. L. Ellis, D. A. Sinclair, J. Dawson, D. B. Allison, Y. Zhang, K. G. Becker, M. Bernier and R. de Cabo (2014). “The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet.” Cell Rep 6(5): 836–843.
- Moskowitz, M. A., E. H. Lo and C. Iadecola (2010). “The science of stroke: mechanisms in search of treatments.” Neuron 67(2): 181–198.
-
Muller, T. D., S. J. Lee, M. Jastroch, D. Kabra, K. Stemmer, M. Aichler, B. Abplanalp, G. Ananthakrishnan, N. Bhardwaj, S. Collins, S. Divanovic, M. Endele, B. Finan, Y. Gao, K. M. Habegger, J. Hembree, K. M. Heppner, S. Hofmann, J. Holland, D. Kuchler, M. Kutschke, R. Krishna, M. Lehti, R. Oelkrug, N. Ottaway, D. Perez-Tilve, C. Raver, A. K. Walch, S. C. Schriever, J. Speakman, Y. H. Tseng, M. Diaz-Meco, P. T. Pfluger, J. Moscat and M. H. Tschop (2013). “p62 links beta-adrenergic input to mitochondrial function and thermogenesis.” J Clin Invest
123(1): 469–478.
10.1172/JCI64209 Google Scholar
- Nakano, Y., K. Hirayama and K. Terao (1987). “Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis.” Arch Neurol 44(1): 103–106.
-
Nebigil, C. G. and L. Maroteaux (2003). “Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure?” Circulation
108(7): 902–908.
10.1161/01.CIR.0000081520.25714.D9 Google Scholar
- Nichols, D. E. and C. D. Nichols (2008). “Serotonin receptors.” Chem Rev 108(5): 1614–1641.
- Nisoli, E., S. Falcone, C. Tonello, V. Cozzi, L. Palomba, M. Fiorani, A. Pisconti, S. Brunelli, A. Cardile, M. Francolini, O. Cantoni, M. O. Carruba, S. Moncada and E. Clementi (2004). “Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals.” Proc Natl Acad Sci U S A 101(47): 16507–16512.
-
Nowak, G., G. L. Clifton, M. L. Godwin and D. Bakajsova (2006). “Activation of ERK1/2 pathway mediates oxidant-induced decreases in mitochondrial function in renal cells.” Am J Physiol Renal Physiol
291(4): F840–F855.
10.1152/ajprenal.00219.2005 Google Scholar
- Ottani, F., R. Latini, L. Staszewsky, L. La Vecchia, N. Locuratolo, M. Sicuro, S. Masson, S. Barlera, V. Milani, M. Lombardi, A. Costalunga, N. Mollichelli, A. Santarelli, N. De Cesare, P. Sganzerla, A. Boi, A. P. Maggioni and U. Limbruno (2016). “Cyclosporine A in reperfused myocardial infarction: the multicenter, controlled, open-label CYCLE trial.” J Am Coll Cardiol 67(4): 365–374.
- Oyinbo, C. A. (2011). “Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade.” Acta Neurobiol Exp (Wars) 71(2): 281–299.
- Pandya, J. D., R. D. Readnower, S. P. Patel, H. M. Yonutas, J. R. Pauly, G. A. Goldstein, A. G. Rabchevsky and P. G. Sullivan (2014). “N-acetylcysteine amide confers neuroprotection, improves bioenergetics and behavioral outcome following TBI.” Exp Neurol 257: 106–113.
- Park, S. J., F. Ahmad, A. Philp, K. Baar, T. Williams, H. Luo, H. Ke, H. Rehmann, R. Taussig, A. L. Brown, M. K. Kim, M. A. Beaven, A. B. Burgin, V. Manganiello and J. H. Chung (2012). “Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.” Cell 148(3): 421–433.
- Patel, S. P., P. G. Sullivan, J. D. Pandya, G. A. Goldstein, J. L. VanRooyen, H. M. Yonutas, K. C. Eldahan, J. Morehouse, D. S. Magnuson and A. G. Rabchevsky (2014). “N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma.” Exp Neurol 257: 95–105.
- Peng, K., Y. Tao, J. Zhang, J. Wang, F. Ye, G. Dan, Y. Zhao, Y. Cai, J. Zhao, Q. Wu, Z. Zou, J. Cao and Y. Sai (2016). “Resveratrol regulates mitochondrial biogenesis and fission/fusion to attenuate rotenone-induced neurotoxicity.” Oxid Med Cell Longev 2016: 6705621.
-
Peterson, Y. K., R. B. Cameron, L. P. Wills, R. E. Trager, C. C. Lindsey, C. C. Beeson and R. G. Schnellmann (2013). “beta2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.” Bioorg Med Chem Lett
23(19): 5376–5381.
10.1016/j.bmcl.2013.07.052 Google Scholar
- Piot, C., P. Croisille, P. Staat, H. Thibault, G. Rioufol, N. Mewton, R. Elbelghiti, T. T. Cung, E. Bonnefoy, D. Angoulvant, C. Macia, F. Raczka, C. Sportouch, G. Gahide, G. Finet, X. Andre-Fouet, D. Revel, G. Kirkorian, J. P. Monassier, G. Derumeaux and M. Ovize (2008). “Effect of cyclosporine on reperfusion injury in acute myocardial infarction.” N Engl J Med 359(5): 473–481.
-
Pisano, A., B. Cerbelli, E. Perli, M. Pelullo, V. Bargelli, C. Preziuso, M. Mancini, L. He, M. G. Bates, J. R. Lucena, P. L. Della Monica, G. Familiari, V. Petrozza, C. Nediani, R. W. Taylor, G. d'Amati and C. Giordano (2016). “Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure.” Cardiovasc Pathol
25(2): 103–112.
10.1016/j.carpath.2015.09.009 Google Scholar
- Protter, A. A., A. M. Wallace, V. A. Ferraris and R. E. Weishaar (1996). “Relaxant effect of human brain natriuretic peptide on human artery and vein tissue.” Am J Hypertens 9(5): 432–436.
- Puigserver, P., J. Rhee, J. Lin, Z. Wu, J. C. Yoon, C. Y. Zhang, S. Krauss, V. K. Mootha, B. B. Lowell and B. M. Spiegelman (2001). “Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1.” Mol Cell 8(5): 971–982.
- Qiao, F., C. Atkinson, M. S. Kindy, A. Shunmugavel, B. P. Morgan, H. Song and S. Tomlinson (2010). “The alternative and terminal pathways of complement mediate post-traumatic spinal cord Inflammation and injury.” Am J Pathol 177(6): 3061–3070.
- Qiao, H., Q. Zhang, H. Yuan, Y. Li, D. Wang, R. Wang and X. He (2015). “Elevated neuronal alpha-synuclein promotes microglia activation after spinal cord ischemic/reperfused injury.” Neuroreport 26(11): 656–661.
- Quintanilla, R. A., Y. N. Jin, K. Fuenzalida, M. Bronfman and G. V. Johnson (2008). “Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.” J Biol Chem 283(37): 25628–25637.
-
Rabchevsky, A. G., I. Fugaccia, P. G. Sullivan and S. W. Scheff (2001). “Cyclosporin A treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing.” J Neurotrauma
18(5): 513–522.
10.1089/089771501300227314 Google Scholar
- Rabchevsky, A. G., S. P. Patel and J. E. Springer (2011). “Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward?” Pharmacol Ther 132(1): 15–29.
- Radomski, M. W., R. M. Palmer and S. Moncada (1990). “An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.” Proc Natl Acad Sci U S A 87(13): 5193–5197.
- Rambert, P., J. Canivet, J. Quichaud and B. Spitz (1961). “Treatment of diabetes mellitus with N,N-dimethyl-biguanide. Experience in 177 cases.” Sem Hop 37: 247–254.
-
Ramirez-Sanchez, I., A. Rodriguez, A. Moreno-Ulloa, G. Ceballos and F. Villarreal (2016). “(-)-Epicatechin-induced recovery of mitochondria from simulated diabetes: potential role of endothelial nitric oxide synthase.” Diab Vasc Dis Res
13(3): 201–210.
10.1177/1479164115620982 Google Scholar
-
Rasbach, K. A., J. A. Funk, T. Jayavelu, P. T. Green and R. G. Schnellmann (2010). “5-hydroxytryptamine receptor stimulation of mitochondrial biogenesis.” J Pharmacol Exp Ther
332(2): 632–639.
10.1124/jpet.109.159947 Google Scholar
- Rasbach, K. A. and R. G. Schnellmann (2008). “Isoflavones promote mitochondrial biogenesis.” J Pharmacol Exp Ther 325(2): 536–543.
- Rayamajhi, N., S. K. Kim, H. Go, Y. Joe, Z. Callaway, J. G. Kang, S. W. Ryter and H. T. Chung (2013). “Quercetin induces mitochondrial biogenesis through activation of HO-1 in HepG2 cells.” Oxid Med Cell Longev 2013: 154279.
- Rehman, H., Y. Krishnasamy, K. Haque, R. G. Thurman, J. J. Lemasters, R. G. Schnellmann and Z. Zhong (2014). “Green tea polyphenols stimulate mitochondrial biogenesis and improve renal function after chronic cyclosporin a treatment in rats.” PLoS One 8(6): e65029.
- Risner, M. E., A. M. Saunders, J. F. Altman, G. C. Ormandy, S. Craft, I. M. Foley, M. E. Zvartau-Hind, D. A. Hosford and A. D. Roses (2006). “Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.” Pharmacogenomics J 6(4): 246–254.
- Robas, N., M. O'Reilly, S. Katugampola and M. Fidock (2003). “Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors.” Curr Opin Pharmacol 3(2): 121–126.
- Rodgers, J. T., C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman and P. Puigserver (2005). “Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.” Nature 434(7029): 113–118.
- Rong, J. X., Y. Qiu, M. K. Hansen, L. Zhu, V. Zhang, M. Xie, Y. Okamoto, M. D. Mattie, H. Higashiyama, S. Asano, J. C. Strum and T. E. Ryan (2007). “Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone.” Diabetes 56(7): 1751–1760.
- Rowland, J. W., G. W. Hawryluk, B. Kwon and M. G. Fehlings (2008). “Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon.” Neurosurg Focus 25(5): E2.
- Russell, R. R., 3rd, R. Bergeron, G. I. Shulman and L. H. Young (1999). “Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR.” Am J Physiol 277(2 Pt 2): H643–H649.
-
Rytinki, M. M. and J. J. Palvimo (2009). “SUMOylation attenuates the function of PGC-1alpha.” J Biol Chem
284(38): 26184–26193.
10.1074/jbc.M109.038943 Google Scholar
-
Ryu, H., J. Lee, S. Impey, R. R. Ratan and R. J. Ferrante (2005). “Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons.” Proc Natl Acad Sci U S A
102(39): 13915–13920.
10.1073/pnas.0502878102 Google Scholar
-
Salloum, F. N., A. Das, A. Samidurai, N. N. Hoke, V. Q. Chau, R. A. Ockaili, J. P. Stasch and R. C. Kukreja (2012). “Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.” Am J Physiol Heart Circ Physiol
302(6): H1347–H1354.
10.1152/ajpheart.00544.2011 Google Scholar
- Sanderson, T. H., C. A. Reynolds, R. Kumar, K. Przyklenk and M. Huttemann (2013). “Molecular mechanisms of ischemia-reperfusion injury in brain: pivotal role of the mitochondrial membrane potential in reactive oxygen species generation.” Mol Neurobiol 47(1): 9–23.
- Sarma, S. (2012). “Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?” Curr Mol Pharmacol 5(2): 255–263.
-
Sasaki, S., Y. Horie and M. Iwata (2007). “Mitochondrial alterations in dorsal root ganglion cells in sporadic amyotrophic lateral sclerosis.” Acta Neuropathol
114(6): 633–639.
10.1007/s00401-007-0299-1 Google Scholar
- Sbert-Roig, M., M. Bauza-Thorbrugge, B. M. Galmes-Pascual, G. Capllonch-Amer, F. J. Garcia-Palmer, I. Llado, A. M. Proenza and M. Gianotti (2016). “GPER mediates the effects of 17beta-estradiol in cardiac mitochondrial biogenesis and function.” Mol Cell Endocrinol 420: 116–124.
- Scarpulla, R. C. (2006). “Nuclear control of respiratory gene expression in mammalian cells.” J Cell Biochem 97(4): 673–683.
- Scarpulla, R. C. (2008). “Transcriptional paradigms in mammalian mitochondrial biogenesis and function.” Physiol Rev 88(2): 611–638.
-
Schenk, L. K., M. M. Rinschen, J. Klokkers, S. M. Kurian, U. Neugebauer, D. R. Salomon, H. Pavenstaedt, E. Schlatter and B. Edemir (2010). “Cyclosporin-A induced toxicity in rat renal collecting duct cells: interference with enhanced hypertonicity induced apoptosis.” Cell Physiol Biochem
26(6): 887–900.
10.1159/000323998 Google Scholar
- Scholpa, N. E., M. K. Lynn, D. Corum, H. A. Boger and R. G. Schnellmann (2017). “ 5-HT1F Receptor-Mediated Mitochondrial Biogenesis for the Treatment of Parkinson's Disease.” Br J Pharmacol.
- Sesso, A., M. M. Marques, M. M. Monteiro, R. I. Schumacher, A. Colquhoun, J. Belizario, S. N. Konno, T. B. Felix, L. A. Botelho, V. Z. Santos, G. R. Da Silva, L. Higuchi Mde and J. T. Kawakami (2004). “Morphology of mitochondrial permeability transition: morphometric volumetry in apoptotic cells.” Anat Rec A Discov Mol Cell Evol Biol 281(2): 1337–1351.
- Sharma, D. R., A. Sunkaria, W. Y. Wani, R. K. Sharma, R. J. Kandimalla, A. Bal and K. D. Gill (2013). “Aluminium induced oxidative stress results in decreased mitochondrial biogenesis via modulation of PGC-1alpha expression.” Toxicol Appl Pharmacol 273(2): 365–380.
- Sharma, D. R., A. Sunkaria, W. Y. Wani, R. K. Sharma, D. Verma, K. Priyanka, A. Bal and K. D. Gill (2015). “Quercetin protects against aluminium induced oxidative stress and promotes mitochondrial biogenesis via activation of the PGC-1α signaling pathway.” Neurotoxicology 51: 116–137.
-
Sharma, V., P. Dhillon, H. Parsons, M. F. Allard and J. H. McNeill (2009). “Metoprolol represses PGC1alpha-mediated carnitine palmitoyltransferase-1B expression in the diabetic heart.” Eur J Pharmacol
607(1–3): 156–166.
10.1016/j.ejphar.2009.02.016 Google Scholar
- Sheng, B., X. Wang, B. Su, H. G. Lee, G. Casadesus, G. Perry and X. Zhu (2012). “Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease.” J Neurochem 120(3): 419–429.
- Skyschally, A., R. Schulz and G. Heusch (2010). “Cyclosporine A at reperfusion reduces infarct size in pigs.” Cardiovasc Drugs Ther 24(1): 85–87.
- St-Pierre, J., S. Drori, M. Uldry, J. M. Silvaggi, J. Rhee, S. Jäger, C. Handschin, K. Zheng, J. Lin and W. Yang (2006). “Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.” Cell 127(2): 397–408.
-
Stallons, L. J., J. A. Funk and R. G. Schnellmann (2013). “Mitochondrial homeostasis in acute organ failure.” Curr Pathobiol Rep
1(3): 169–177.
10.1007/s40139-013-0023-x Google Scholar
- Szalowska, E., T. E. Pronk and A. A. Peijnenburg (2015). “Cyclosporin A induced toxicity in mouse liver slices is only slightly aggravated by Fxr-deficiency and co-occurs with upregulation of pro-inflammatory genes and downregulation of genes involved in mitochondrial functions.” BMC Genomics 16: 822.
- Tabrizi, S. J., M. W. J. Cleeter, J. Xuereb, J. W. Taanman, J. M. Cooper and A. H. V. Schapira (1999). “Biochemical abnormalities and excitotoxicity in Huntington's disease brain.” Ann Neurol 45(1): 25–32.
- Takizawa, Y., R. Nakata, K. Fukuhara, H. Yamashita, H. Kubodera and H. Inoue (2015). “The 4′-hydroxyl group of resveratrol is functionally important for direct activation of PPARalpha.” PLoS One 10(3): e0120865.
- Tator, C. H. and M. G. Fehlings (1991). “Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms.” J Neurosurg 75(1): 15–26.
- Tedesco, L., A. Valerio, C. Cervino, A. Cardile, C. Pagano, R. Vettor, R. Pasquali, M. O. Carruba, G. Marsicano, B. Lutz, U. Pagotto and E. Nisoli (2008). “Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.” Diabetes 57(8): 2028–2036.
- Tedesco, L., A. Valerio, M. Dossena, A. Cardile, M. Ragni, C. Pagano, U. Pagotto, M. O. Carruba, R. Vettor and E. Nisoli (2010). “Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways.” Diabetes 59(11): 2826–2836.
- Teyssier, C., H. Ma, R. Emter, A. Kralli and M. R. Stallcup (2005). “Activation of nuclear receptor coactivator PGC-1alpha by arginine methylation.” Genes Dev 19(12): 1466–1473.
- Thadhani, R., M. Pascual and J. V. Bonventre (1996). “Acute renal failure.” N Engl J Med 334(22): 1448–1460.
- Timmers, S., E. Konings, L. Bilet, R. H. Houtkooper, T. van de Weijer, G. H. Goossens, J. Hoeks, S. van der Krieken, D. Ryu, S. Kersten, E. Moonen-Kornips, M. K. Hesselink, I. Kunz, V. B. Schrauwen-Hinderling, E. E. Blaak, J. Auwerx and P. Schrauwen (2011). “Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans.” Cell Metab 14(5): 612–622.
- Tong, C., A. Morrison, S. Mattison, S. Qian, M. Bryniarski, B. Rankin, J. Wang, D. P. Thomas and J. Li (2013). “Impaired SIRT1 nucleocytoplasmic shuttling in the senescent heart during ischemic stress.” FASEB J 27(11): 4332–4342.
- Totoiu, M. O. and H. S. Keirstead (2005). “Spinal cord injury is accompanied by chronic progressive demyelination.” J Comp Neurol 486(4): 373–383.
- Tran, M., D. Tam, A. Bardia, M. Bhasin, G. C. Rowe, A. Kher, Z. K. Zsengeller, M. R. Akhavan-Sharif, E. V. Khankin, M. Saintgeniez, S. David, D. Burstein, S. A. Karumanchi, I. E. Stillman, Z. Arany and S. M. Parikh (2011). “PGC-1alpha promotes recovery after acute kidney injury during systemic inflammation in mice.” J Clin Invest 121(10): 4003–4014.
- Tuteja, N. (2009). “Signaling through G protein coupled receptors.” Plant Signal Behav 4(10): 942–947.
-
Van Den Bosch, L., W. Vandenberghe, H. Klaassen, E. Van Houtte and W. Robberecht (2000). “Ca2+-permeable AMPA receptors and selective vulnerability of motor neurons.” J Neurol Sci
180(1–2): 29–34.
10.1016/S0022-510X(00)00414-7 Google Scholar
- Vanhoutte, P. M. and T. F. Luscher (1986). “Serotonin and the blood vessel wall.” J Hypertens Suppl 4(1): S29–S35.
- Ventura-Clapier, R., A. Garnier and V. Veksler (2008). “Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha.” Cardiovasc Res 79(2): 208–217.
- Vielhaber, S., D. Kunz, K. Winkler, F. R. Wiedemann, E. Kirches, H. Feistner, H. J. Heinze, C. E. Elger, W. Schubert and W. S. Kunz (2000). “Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis.” Brain 123(7): 1339–1348.
- Vingtdeux, V., L. Giliberto, H. Zhao, P. Chandakkar, Q. Wu, J. E. Simon, E. M. Janle, J. Lobo, M. G. Ferruzzi, P. Davies and P. Marambaud (2010). “AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.” J Biol Chem 285(12): 9100–9113.
- Wang, B., J. Sun, Y. Ma, G. Wu, Y. Tian, Y. Shi and G. Le (2014a). “Resveratrol preserves mitochondrial function, stimulates mitochondrial biogenesis, and attenuates oxidative stress in regulatory T cells of mice fed a high-fat diet.” J Food Sci 79(9): H1823–H1831.
-
Wang, J. and G.-J. Chen (2016). “Mitochondria as a therapeutic target in Alzheimer's disease.” Genes Dis
3(3): 220–227.
10.1016/j.gendis.2016.05.001 Google Scholar
- Wang, K. Z., J. Zhu, R. K. Dagda, G. Uechi, S. J. Cherra 3rd, A. M. Gusdon, M. Balasubramani and C. T. Chu (2014b). “ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: implications for Parkinson's disease.” Mitochondrion 17: 132–140.
- Watson, G. S., B. A. Cholerton, M. A. Reger, L. D. Baker, S. R. Plymate, S. Asthana, M. A. Fishel, J. J. Kulstad, P. S. Green, D. G. Cook, S. E. Kahn, M. L. Keeling and S. Craft (2005). “Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.” Am J Geriatr Psychiatry 13(11): 950–958.
-
West, T., M. Atzeva and D. M. Holtzman (2007). “Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury.” Dev Neurosci
29(4–5): 363–372.
10.1159/000105477 Google Scholar
- Weydt, P., V. V. Pineda, A. E. Torrence, R. T. Libby, T. F. Satterfield, E. Lazarowski, M. L. Gilbert, G. J. Morton, T. K. Bammler, A. D. Strand, L. Cui, R. P. Beyer, C. N. Easley, A. C. Smith, D. Krainc, S. Luquet, I. Sweet, M. W. Schwartz and A. R. La Spada (2006). “Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration.” Cell Metab 4(5): 349–362.
- Whitaker, R. M., D. Corum, C. C. Beeson and R. G. Schnellmann (2016). “Mitochondrial biogenesis as a pharmacological target: a new approach to acute and chronic diseases.” Annu Rev Pharmacol Toxicol 56: 229–249.
- Whitaker, R. M., L. P. Wills, L. J. Stallons and R. G. Schnellmann (2013). “cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury.” J Pharmacol Exp Ther 347(3): 626–634.
- Wiedemann, F. R., G. Manfredi, C. Mawrin, M. Flint Beal and E. A. Schon (2002). “Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients.” J Neurochem 80(4): 616–625.
-
Wills, L. P., R. E. Trager, G. C. Beeson, C. C. Lindsey, Y. K. Peterson, C. C. Beeson and R. G. Schnellmann (2012). “The beta2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis.” J Pharmacol Exp Ther
342(1): 106–118.
10.1124/jpet.112.191528 Google Scholar
- Wu, H., S. B. Kanatous, F. A. Thurmond, T. Gallardo, E. Isotani, R. Bassel-Duby and R. S. Williams (2002). “Regulation of mitochondrial biogenesis in skeletal muscle by CaMK.” Science 296(5566): 349–352.
- Wu, Q. Q., Y. Wang, M. Senitko, C. Meyer, W. C. Wigley, D. A. Ferguson, E. Grossman, J. Chen, X. J. Zhou, J. Hartono, P. Winterberg, B. Chen, A. Agarwal and C. Y. Lu (2011). “Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1.” Am J Physiol Renal Physiol 300(5): F1180–F1192.
- Wu, Z., P. Puigserver, U. Andersson, C. Zhang, G. Adelmant, V. Mootha, A. Troy, S. Cinti, B. Lowell, R. C. Scarpulla and B. M. Spiegelman (1999). “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1.” Cell 98(1): 115–124.
- Yan, M. H., X. Wang and X. Zhu (2013). “Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.” Free Radic Biol Med 62: 90–101.
- Ye, L., J. Wu, P. Cohen, L. Kazak, M. J. Khandekar, M. P. Jedrychowski, X. Zeng, S. P. Gygi and B. M. Spiegelman (2013a). “Fat cells directly sense temperature to activate thermogenesis.” Proc Natl Acad Sci U S A 110(30): 12480–12485.
-
Ye, Y., J. Qian, A. C. Castillo, S. Ling, H. Ye, J. R. Perez-Polo, M. Bajaj and Y. Birnbaum (2013b). “Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.” Am J Physiol Heart Circ Physiol
304(1): H131–H141.
10.1152/ajpheart.00609.2012 Google Scholar
- Yin, W., A. P. Signore, M. Iwai, G. Cao, Y. Gao and J. Chen (2008). “Rapidly increased neuronal mitochondrial biogenesis after hypoxic-ischemic brain injury.” Stroke 39(11): 3057–3063.
-
Zhang, L., M. Frederich, H. He and J. A. Balschi (2006). “Relationship between 5-aminoimidazole-4-carboxamide-ribotide and AMP-activated protein kinase activity in the perfused mouse heart.” Am J Physiol Heart Circ Physiol
290(3): H1235–H1243.
10.1152/ajpheart.00906.2005 Google Scholar
-
Zolezzi, J. M., C. Silva-Alvarez, D. Ordenes, J. A. Godoy, F. J. Carvajal, M. J. Santos and N. C. Inestrosa (2013). “Peroxisome proliferator-activated receptor (PPAR) gamma and PPARalpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders?” PLoS One
8(5): e64019.
10.1371/journal.pone.0064019 Google Scholar
-
Zuo, L., Q. Li, B. Sun, Z. Xu and Z. Ge (2013). “Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1alpha.” Biochem Biophys Res Commun
433(1): 52–57.
10.1016/j.bbrc.2013.02.068 Google Scholar
